HealthcareLarge capRs 67,718 crRs 140.2 cr traded a dayHealthcarePharmaceuticals
Close on 2026-08-21
415.55
+0.74%
52-week range75% of the way up
338.90440.70
Market cap
67,718 cr
P/E (TTM)
162.6×
industry 44×
EPS (TTM)
2.56
Revenue YoY
+10.0%
Q1 FY27
Profit YoY
+53.4%
Net margin
3.2%
+0.9pt vs a year ago
Growth trend
+7.7pt
vs last quarter’s YoY
1 month
-4.5%
Below 52w high
6.1%
RSI (14)
41
Daily swing
2.0%
average true range
Volume
0.6×
vs 20-day average
Traded
Rs 140 cr
median day
Close200-day averageMaterial filing
260 sessions · hover for the filing behind a move
1 week
−0.35%
1 month
−4.52%
3 months
−4.72%
6 months
+5.24%
1 year
+16.69%
The read
written from the numbers on this page
The evidence is mixed4 supporting, 3 against, 1 worth knowing
Supporting
trading 5% above its 200-day average
up 17% over twelve months
4 independent kinds of evidence agree today, which is uncommon
revenue grew 10% year on year in the quarter ending 2026-06-30
Against
1 of the scans it matches has historically underperformed the market
priced at 163× earnings against an industry median of 44× — 269% above its peers
futures show a short buildup — new sellers are committing capital
Worth knowing
the 50-day and 200-day averages disagree, which usually means a turn in progress rather than a trend to lean on
BIOCON sits in Healthcare, Pharmaceuticals — worth checking whether the whole group is moving together or whether this name is doing it alone.
What would change this read: a close below 395, its 200-day average; open interest reversing while price keeps going.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.
What is working, what is not
read from the filings, with the figure behind every line
Working3
Net profit +53.4% year on year, Rs 89 cr to Rs 137 cr.
+53.4%Rs 89 crRs 137 cr
Profit grew faster than revenue, +53.4% against +10.0%.
+53.4%+10.0%
Revenue +10.0% year on year, Rs 3,942 cr to Rs 4,336 cr.
+10.0%Rs 3,942 crRs 4,336 cr
Needs watching
Nothing in the filings stands out either way.
Every figure here is computed from the company’s own filings. The wording is generated directly from the figures.
How it has performed
price return over each window, measured against zero
What the scans say today
5 of 47 matched on 2026-08-21
BIOCON matches 5 of the 47 scans today, across 4 different kinds of evidence. Three or more independent families agreeing is uncommon — it is the same test the shortlist on every page uses.
BIOCON trades at 163× trailing earnings, above its median of 81× over this window — 102% more expensive than usual. The band runs from the 5th to the 95th percentile, so single-day spikes do not set the edges.
This window is short by the standards of valuation history — it begins where four quarters of filed earnings first exist. A stock can look cheap against two years and expensive against ten.
Other filing filings were typically -0.08pt vs the market over the next 5 sessions (n=12,093) · Analyst call filings were typically +0.14pt vs the market over the next 5 sessions (n=3,352) · AGM / EGM filings were typically +0.00pt vs the market over the next 5 sessions (n=4,362)
The business
from the company’s filed results
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.
Going for it
revenue grew 10% against the same quarter a year earlier
profit rose 53% year on year
Going against it
net margin narrowed from 4.4% to 3.2%
Quarter-by-quarter numbers, as filed
Quarter
Revenue
Profit before tax
Net profit
EPS
Net margin
Q1 FY27
2026-06-30 · consolidated
4,336
128
137
0.87
3.2%
Q4 FY26
2026-03-31 · consolidated
4,517
248
199
0.79
4.4%
Q3 FY26
2025-12-31 · consolidated
4,173
-68
-52
1.08
-1.2%
Q2 FY26
2025-09-30 · consolidated
4,296
171
133
0.66
3.1%
Q1 FY26
2025-06-30 · consolidated
3,942
97
89
0.26
2.3%
Q4 FY25
2025-03-31 · consolidated
4,417
487
459
2.88
10.4%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.
Where the price stands
the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average-1.7%
Versus 200-day average+5.3%
Below 52-week high-5.7%
Above 52-week low+22.6%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)40.5
Higher closes in last 52 of 5
Six-month return+5.24%
Risk and liquidity
What a position costs to hold and to exit. Position sizing starts with the daily swing, not with conviction.
Typical daily swing (ATR)2.04%
Volume versus 20-day0.6x
Median daily turnoverRs 140.2 cr
Derivatives
near expiry 2026-08-25 · 2026-08-20
Short Buildup
Price down, open interest up. New sellers are committing capital. The most common state in a falling tape, and the one that unwinds hardest if it turns.
Futures basis versus spot+0.15%
Open interest change+3.6%
Put / call ratio0.68
Put wall (support)410
Call wall (resistance)430
Max pain420
How to read this
Open interest is contracts still open, so a rise means new positions and a fall means positions closing. Combined with price direction that gives the state on the left. The walls are the strikes carrying the most open interest near expiry — levels other people are watching, not levels the price is obliged to respect. A future below spot means sellers are paying to be short.
Peers
Healthcare · 67 classified companies
BIOCON trades at 162.6× trailing earnings against an industry median of 44.0× across 64 other classified companies in its industry — more expensive than them, by 269%. A multiple is a statement about expectations, not about quality: cheap usually means the market expects less, and it is often right.